Investors have not reacted well to Indivior plc's business update and bad news on earnings plus a schizophrenia drug that is no longer commercially viable have sent the UK firm's share price to the floor.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?